Keywords:
Pelvis, Abdomen, Oncology, MR, MR-Diffusion/Perfusion, Contrast agent-intravenous, Biopsy, Imaging sequences, Cancer, Neoplasia, Outcomes
Authors:
E. Demozzi, F. M. Cavicchioli, L. Romano, G. Foti, M. Pastorello, A. Molinari, S. Cavalleri, G. Carbognin; Negrar/IT
DOI:
10.1594/ecr2018/C-1174
Aims and objectives
Prostate cancer (PCa) is the second most common cancer in men worldwide [1,2]; it is a heterogeneous disease that ranges clinically from indolent to highly aggressive.
The prevalence of prostate cancer increases with age; 34% of men in the 5th decade of life and up to 70% aged 80 years or older have histologic evidence of prostate cancer.
Sixteen percent of males will develop prostate cancer during their lifetime [3-5],
but only a small proportion of those patients will die because of PCa.
Multiparametric Magnetic Resonance Imaging (mpMRI) can be considered nowadays a common exam performed for different indications,
including staging of locally advanced cancer,
monitoring active survaillance of a known prostate tumor,
tumor detection and localization,
characterization,
risk stratification and image guidance for biopsy,
surgery,focal therapy and radiation therapy [6-10].
The purpose of our study is to determine the negative predictive value (NPV) of multiparametric MRI (mpMRI) to exclude clinically significant prostate cancer (PCa) in comparison with histopathological results after transrectal ultrasound (TRUS)-guided biopsies.